1887
Surveillance Open Access
Like 0

Abstract

Background

Ending the HIV pandemic must involve new tools to rapidly identify and control local outbreaks and prevent the emergence of recombinant strains with epidemiological advantages.

Aim

This observational study aimed to investigate in France a cluster of HIV-1 cases related to a new circulating recombinant form (CRF). The confirmation this CRF’s novelty as well as measures to control its spread are presented.

Methods

Phylogenetic analyses of HIV sequences routinely generated for drug resistance genotyping before 2018 in French laboratories were employed to detect the transmission chain. The CRF involved was characterised by almost full-length viral sequencing for six cases. Cases’ clinical data were reviewed. Where possible, epidemiological information was collected with a questionnaire.

Results

The transmission cluster comprised 49 cases, mostly diagnosed in 2016–2017 (n = 37). All were infected with a new CRF, CRF94_cpx. The molecular proximity of this CRF to X4 strains and the high median viraemia, exceeding 5.0 log copies/mL, at diagnosis, even in chronic infection, raise concerns of enhanced virulence. Overall, 41 cases were diagnosed in the Ile-de-France region and 45 were men who have sex with men. Among 24 cases with available information, 20 reported finding partners through a geosocial networking app. Prevention activities in the area and population affected were undertaken.

Conclusion

We advocate the systematic use of routinely generated HIV molecular data by a dedicated reactive network, to improve and accelerate targeted prevention interventions. Geosocial networking apps can play a role in the spread of outbreaks, but could also deliver local targeted preventive alerts.

Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2019.24.39.1800658
2019-09-26
2019-10-23
http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2019.24.39.1800658
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/24/39/eurosurv-24-39-4.html?itemId=/content/10.2807/1560-7917.ES.2019.24.39.1800658&mimeType=html&fmt=ahah

References

  1. 90-90-90 - An ambitious treatment target to help end the AIDS epidemic. [Accessed: 6 Aug 2018]. Available from: http://www.unaids.org/en/resources/documents/2017/90-90-90
  2. Eisinger RW, Fauci AS. Ending the HIV/AIDS Pandemic1. Emerg Infect Dis. 2018;24(3):413-6.  https://doi.org/10.3201/eid2403.171797  PMID: 29460740 
  3. Haar K, Amato-Gauci AJ. European men who have sex with men still at risk of HIV infection despite three decades of prevention efforts. Euro Surveill. 2015;20(14):21087.  https://doi.org/10.2807/1560-7917.ES2015.20.14.21087  PMID: 25884146 
  4. Pharris A, Quinten C, Tavoschi L, Spiteri G, Amato-Gauci AJECDC HIV/AIDS Surveillance Network. Trends in HIV surveillance data in the EU/EEA, 2005 to 2014: new HIV diagnoses still increasing in men who have sex with men. Euro Surveill. 2015;20(47):30071.  https://doi.org/10.2807/1560-7917.ES.2015.20.47.30071  PMID: 26625124 
  5. Molina J-M, Capitant C, Spire B, Pialoux G, Cotte L, Charreau I, et al. On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection. N Engl J Med. 2015;373(23):2237-46.  https://doi.org/10.1056/NEJMoa1506273  PMID: 26624850 
  6. McCormack S, Dunn DT, Desai M, Dolling DI, Gafos M, Gilson R, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet. 2016;387(10013):53-60.  https://doi.org/10.1016/S0140-6736(15)00056-2  PMID: 26364263 
  7. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587-99.  https://doi.org/10.1056/NEJMoa1011205  PMID: 21091279 
  8. Oster AM, France AM, Mermin J. Molecular epidemiology and the transformation of hiv prevention. JAMA. 2018;319(16):1657-8.  https://doi.org/10.1001/jama.2018.1513  PMID: 29630701 
  9. Poon AFY, Gustafson R, Daly P, Zerr L, Demlow SE, Wong J, et al. Near real-time monitoring of HIV transmission hotspots from routine HIV genotyping: an implementation case study. Lancet HIV. 2016;3(5):e231-8.  https://doi.org/10.1016/S2352-3018(16)00046-1  PMID: 27126490 
  10. Chaillon A, Essat A, Frange P, Smith DM, Delaugerre C, Barin F, et al. Spatiotemporal dynamics of HIV-1 transmission in France (1999-2014) and impact of targeted prevention strategies. Retrovirology. 2017;14(1):15.  https://doi.org/10.1186/s12977-017-0339-4  PMID: 28222757 
  11. Wang X, Wu Y, Mao L, Xia W, Zhang W, Dai L, et al. Targeting HIV Prevention Based on Molecular Epidemiology Among Deeply Sampled Subnetworks of Men Who Have Sex With Men. Clin Infect Dis. 2015;61(9):1462-8.  https://doi.org/10.1093/cid/civ526  PMID: 26129754 
  12. Mehta SR, Chaillon A, Gaines TL, Gonzalez-Zuniga PE, Stockman JK, Almanza-Reyes H, et al. Impact of Public Safety Policies on Human Immunodeficiency Virus Transmission Dynamics in Tijuana, Mexico. Clin Infect Dis. 2018;66(5):758-64.  https://doi.org/10.1093/cid/cix884  PMID: 29045592 
  13. Leoz M, Feyertag F, Charpentier C, Delaugerre C, Wirden M, Lemee V, et al. Characterization of CRF56_cpx, a new circulating B/CRF02/G recombinant form identified in MSM in France. AIDS. 2013;27(14):2309-12.  https://doi.org/10.1097/QAD.0b013e3283632e0c  PMID: 24157908 
  14. Villabona Arenas CJ, Vidal N, Ahuka Mundeke S, Muwonga J, Serrano L, Muyembe JJ, et al. Divergent HIV-1 strains (CRF92_C2U and CRF93_cpx) co-circulating in the Democratic Republic of the Congo: Phylogenetic insights on the early evolutionary history of subtype C. Virus Evol. 2017;3(2):vex032.  https://doi.org/10.1093/ve/vex032  PMID: 29250430 
  15. González-Domenech CM, Viciana I, Delaye L, Mayorga ML, Palacios R, de la Torre J, et al. Emergence as an outbreak of the HIV-1 CRF19_cpx variant in treatment-naïve patients in southern Spain. PLoS One. 2018;13(1):e0190544.  https://doi.org/10.1371/journal.pone.0190544  PMID: 29309418 
  16. Recordon-Pinson P, Alves BM, Tumiotto C, Bellecave P, Bonnet F, Neau D, et al. A new HIV-1 circulating recombinant form (CRF98_cpx) between CRF06_cpx and subtype B identified in Southwestern France. AIDS Res Hum Retroviruses. 2018;34(11):1005-9.  https://doi.org/10.1089/aid.2018.0122  PMID: 29947242 
  17. Raymond S, Delobel P, Mavigner M, Cazabat M, Souyris C, Encinas S, et al. Development and performance of a new recombinant virus phenotypic entry assay to determine HIV-1 coreceptor usage. J Clin Virol. 2010;47(2):126-30.  https://doi.org/10.1016/j.jcv.2009.11.018  PMID: 20015684 
  18. Leoz M, Chaix M-L, Delaugerre C, Rivoisy C, Meyer L, Rouzioux C, et al. Circulation of multiple patterns of unique recombinant forms B/CRF02_AG in France: precursor signs of the emergence of an upcoming CRF B/02. AIDS. 2011;25(11):1371-7.  https://doi.org/10.1097/QAD.0b013e328347c060  PMID: 21522007 
  19. Ngoupo PA, Sadeuh-Mba SA, De Oliveira F, Ngono V, Ngono L, Tchendjou P, et al. First evidence of transmission of an HIV-1 M/O intergroup recombinant virus. AIDS. 2016;30(1):1-8. PMID: 26731750 
  20. Descamps D, Assoumou L, Chaix M-L, Chaillon A, Pakianather S, de Rougemont A, et al. ANRS AC11 Resistance Study Group. National sentinel surveillance of transmitted drug resistance in antiretroviral-naive chronically HIV-infected patients in France over a decade: 2001-2011. J Antimicrob Chemother. 2013;68(11):2626-31.  https://doi.org/10.1093/jac/dkt238  PMID: 23798669 
  21. Saag MS, Benson CA, Gandhi RT, Hoy JF, Landovitz RJ, Mugavero MJ, et al. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society-USA Panel. JAMA. 2018;320(4):379-96.  https://doi.org/10.1001/jama.2018.8431  PMID: 30043070 
  22. Blanquart F, Wymant C, Cornelissen M, Gall A, Bakker M, Bezemer D, et al. Viral genetic variation accounts for a third of variability in HIV-1 set-point viral load in Europe. PLoS Biol. 2017;15(6):e2001855.  https://doi.org/10.1371/journal.pbio.2001855  PMID: 28604782 
  23. Frange P, Meyer L, Ghosn J, Deveau C, Goujard C, Duvivier C, et al. Prevalence of CXCR4-tropic viruses in clustered transmission chains at the time of primary HIV-1 infection. Clin Microbiol Infect. 2013;19(5):E252-5.  https://doi.org/10.1111/1469-0691.12127  PMID: 23331764 
  24. Beretta M, Moreau A, Bouvin-Pley M, Essat A, Goujard C, Chaix M-L, et al. ANRS 06 Primo Cohort. Phenotypic properties of envelope glycoproteins of transmitted HIV-1 variants from patients belonging to transmission chains. AIDS. 2018;32(14):1917-26.  https://doi.org/10.1097/QAD.0000000000001906  PMID: 29927786 
  25. Cavarelli M, Foglieni C, Rescigno M, Scarlatti G. R5 HIV-1 envelope attracts dendritic cells to cross the human intestinal epithelium and sample luminal virions via engagement of the CCR5. EMBO Mol Med. 2013;5(5):776-94.  https://doi.org/10.1002/emmm.201202232  PMID: 23606583 
  26. Sarrami-Forooshani R, Mesman AW, van Teijlingen NH, Sprokholt JK, van der Vlist M, Ribeiro CMS, et al. Human immature Langerhans cells restrict CXCR4-using HIV-1 transmission. Retrovirology. 2014;11(1):52.  https://doi.org/10.1186/1742-4690-11-52  PMID: 24990163 
  27. Schuitemaker H, Koot M, Kootstra NA, Dercksen MW, de Goede RE, van Steenwijk RP, et al. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population. J Virol. 1992;66(3):1354-60. PMID: 1738194 
  28. Berger EA, Murphy PM, Farber JM. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol. 1999;17(1):657-700.  https://doi.org/10.1146/annurev.immunol.17.1.657  PMID: 10358771 
  29. Daar ES, Kesler KL, Petropoulos CJ, Huang W, Bates M, Lail AE, et al. Baseline HIV type 1 coreceptor tropism predicts disease progression. Clin Infect Dis. 2007;45(5):643-9.  https://doi.org/10.1086/520650  PMID: 17683002 
  30. Cornelisse VJ, Fairley CK, Stoove M, Asselin J, Chow EPF, Price B, et al. Evaluation of Preexposure (PrEP) Eligibility Criteria, Using Sexually Transmissible Infections as Markers of Human Immunodeficiency Virus (HIV) Risk at Enrollment in PrEPX, a Large Australian HIV PrEP Trial. Clin Infect Dis. 2018;67(12):1847-52.  https://doi.org/10.1093/cid/ciy370  PMID: 29741665 
  31. Duncan DT, Park SH, Hambrick HR, Dangerfield DT 2ndGoedel WC, Brewer R, et al. Characterizing Geosocial-Networking App Use Among Young Black Men Who Have Sex With Men: A Multi-City Cross-Sectional Survey in the Southern United States. JMIR Mhealth Uhealth. 2018;6(6):e10316.  https://doi.org/10.2196/10316  PMID: 29903702 
/content/10.2807/1560-7917.ES.2019.24.39.1800658
Loading

Data & Media loading...

Comment has been disabled for this content
Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error